JP2016065042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016065042A5 JP2016065042A5 JP2015172636A JP2015172636A JP2016065042A5 JP 2016065042 A5 JP2016065042 A5 JP 2016065042A5 JP 2015172636 A JP2015172636 A JP 2015172636A JP 2015172636 A JP2015172636 A JP 2015172636A JP 2016065042 A5 JP2016065042 A5 JP 2016065042A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- dichlorophenyl
- carboxy
- benzoxazole
- raman
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- TXEIIPDJKFWEEC-UHFFFAOYSA-N tafamidis Chemical compound O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 TXEIIPDJKFWEEC-UHFFFAOYSA-N 0.000 claims 9
- 238000001069 Raman spectroscopy Methods 0.000 claims 5
- 238000001237 Raman spectrum Methods 0.000 claims 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims 5
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 5
- 238000001228 spectrum Methods 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 239000013078 crystal Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 108010071690 Prealbumin Proteins 0.000 claims 1
- 102000009190 Transthyretin Human genes 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019218244A JP7357525B2 (ja) | 2014-09-08 | 2019-12-02 | ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047614P | 2014-09-08 | 2014-09-08 | |
| US62/047,614 | 2014-09-08 | ||
| US201562203953P | 2015-08-12 | 2015-08-12 | |
| US62/203,953 | 2015-08-12 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019218244A Division JP7357525B2 (ja) | 2014-09-08 | 2019-12-02 | ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016065042A JP2016065042A (ja) | 2016-04-28 |
| JP2016065042A5 true JP2016065042A5 (enExample) | 2018-08-02 |
Family
ID=54199901
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015172636A Withdrawn JP2016065042A (ja) | 2014-09-08 | 2015-09-02 | ６−カルボキシ−２−（３，５−ジクロロフェニル）−ベンゾオキサゾールの結晶性固体形態 |
| JP2019218244A Active JP7357525B2 (ja) | 2014-09-08 | 2019-12-02 | ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態 |
| JP2021182622A Withdrawn JP2022024014A (ja) | 2014-09-08 | 2021-11-09 | ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態 |
| JP2023115087A Pending JP2023134645A (ja) | 2014-09-08 | 2023-07-13 | ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態 |
| JP2025066606A Pending JP2025108584A (ja) | 2014-09-08 | 2025-04-15 | ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019218244A Active JP7357525B2 (ja) | 2014-09-08 | 2019-12-02 | ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態 |
| JP2021182622A Withdrawn JP2022024014A (ja) | 2014-09-08 | 2021-11-09 | ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態 |
| JP2023115087A Pending JP2023134645A (ja) | 2014-09-08 | 2023-07-13 | ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態 |
| JP2025066606A Pending JP2025108584A (ja) | 2014-09-08 | 2025-04-15 | ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9770441B1 (enExample) |
| EP (3) | EP4349406B1 (enExample) |
| JP (5) | JP2016065042A (enExample) |
| KR (1) | KR102004059B1 (enExample) |
| CN (2) | CN115368313A (enExample) |
| AU (1) | AU2015313875B2 (enExample) |
| BR (1) | BR112017003421B1 (enExample) |
| CA (1) | CA2903194A1 (enExample) |
| CY (1) | CY1124843T1 (enExample) |
| DK (2) | DK4349406T3 (enExample) |
| ES (2) | ES2975633T3 (enExample) |
| FI (2) | FI3977993T3 (enExample) |
| HR (1) | HRP20211834T1 (enExample) |
| HU (2) | HUE056583T2 (enExample) |
| IL (1) | IL251037B1 (enExample) |
| LT (1) | LT3191461T (enExample) |
| MX (1) | MX374012B (enExample) |
| PL (2) | PL3977993T3 (enExample) |
| PT (3) | PT3191461T (enExample) |
| RS (1) | RS62634B1 (enExample) |
| SG (1) | SG11201700958YA (enExample) |
| SI (3) | SI3191461T1 (enExample) |
| TW (1) | TWI644902B (enExample) |
| WO (1) | WO2016038500A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571950A (en) * | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| WO2020128816A2 (en) | 2018-12-20 | 2020-06-25 | Pfizer Inc. | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent |
| US12116352B2 (en) | 2019-04-11 | 2024-10-15 | Inke, S.A. | Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate |
| KR102911660B1 (ko) * | 2019-05-16 | 2026-01-14 | 아시아 케미컬 인더스트리스 리미티드 | 타파미디스의 고상형 및 그 염 |
| WO2021001858A1 (en) * | 2019-07-04 | 2021-01-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| JP2023503833A (ja) | 2019-11-15 | 2023-02-01 | ▲蘇▼州科睿思制▲葯▼有限公司 | タファミジスの結晶形及びその調製方法及びその使用 |
| CA3165298A1 (en) | 2019-12-20 | 2021-06-24 | Pfizer Ireland Pharmaceuticals | Efficient process for making 6-carboxy benzoxazole derivatives |
| WO2021152623A1 (en) * | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
| WO2021232619A1 (zh) * | 2020-05-19 | 2021-11-25 | 苏州科睿思制药有限公司 | 一种他发米帝司游离酸的晶型及其制备方法和用途 |
| WO2022009221A1 (en) * | 2020-07-04 | 2022-01-13 | Nuray Chemicals Private Limited | Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof |
| WO2022084790A1 (en) * | 2020-10-19 | 2022-04-28 | Glenmark Life Sciences Limited | Process for preparation of tafamidis and salts thereof |
| WO2022107166A1 (en) * | 2020-11-20 | 2022-05-27 | Natco Pharma Limited | Novel crystalline form of tafamidis and its process thereof |
| WO2022112919A1 (en) | 2020-11-25 | 2022-06-02 | Pfizer Inc. | (aza)benzothiazolyl substituted pyrazole compounds |
| CN114907283B (zh) * | 2021-02-07 | 2025-01-28 | 南京正大天晴制药有限公司 | 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法 |
| CN114989106A (zh) * | 2021-02-09 | 2022-09-02 | 齐鲁制药有限公司 | 氯苯唑酸的新晶型及其制备方法 |
| EP4083027A1 (en) * | 2021-04-26 | 2022-11-02 | Química Sintética, S.A. | A solid state form of tafamidis and a process for its preparation |
| WO2023020762A1 (en) | 2021-08-16 | 2023-02-23 | Synthon B.V. | Crystalline forms of tafamidis nicotinamide adduct |
| JP2024541422A (ja) | 2021-11-17 | 2024-11-08 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | タファミジスの固体状態の形態 |
| CN119604278A (zh) | 2022-07-28 | 2025-03-11 | 辉瑞大药厂 | 氯苯唑酸药物组合物 |
| EP4605382A1 (en) * | 2022-10-17 | 2025-08-27 | Biophore India Pharmaceuticals Pvt. Ltd. | A process for the preparation of crystalline form of tafamidis |
| US11980685B1 (en) | 2022-12-23 | 2024-05-14 | Tap Pharmaceuticals, Ag | Liquid pharmaceutical formulations of tafamidis |
| US11878081B1 (en) | 2022-12-23 | 2024-01-23 | Tap Pharmaceuticals Ag | Pharmaceutical formulations of tafamidis |
| WO2026050334A1 (en) | 2024-08-29 | 2026-03-05 | Alexion Pharmaceuticals, Inc. | Transthyretin stabilizers and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| CN101413143B (zh) * | 2002-12-19 | 2013-09-18 | 斯克里普斯研究学院 | 稳定甲状腺素运载蛋白和抑制甲状腺素运载蛋白错折叠的组合物和方法 |
| CN103951583B (zh) * | 2006-12-06 | 2016-01-06 | 科内图斯医药公司 | 一种抑制剂的结晶形式 |
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| WO2013038351A1 (en) * | 2011-09-16 | 2013-03-21 | Pfizer Inc. | Solid forms of a transthyretin dissociation inhibitor |
| WO2013168014A1 (en) * | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| GB2571950A (en) | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| KR102911660B1 (ko) | 2019-05-16 | 2026-01-14 | 아시아 케미컬 인더스트리스 리미티드 | 타파미디스의 고상형 및 그 염 |
| WO2021001858A1 (en) | 2019-07-04 | 2021-01-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| WO2021152623A1 (en) | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
-
2015
- 2015-08-31 CN CN202211071641.7A patent/CN115368313A/zh active Pending
- 2015-08-31 FI FIEP21203965.5T patent/FI3977993T3/fi active
- 2015-08-31 PL PL21203965.5T patent/PL3977993T3/pl unknown
- 2015-08-31 AU AU2015313875A patent/AU2015313875B2/en active Active
- 2015-08-31 PT PT157712761T patent/PT3191461T/pt unknown
- 2015-08-31 LT LTEPPCT/IB2015/056597T patent/LT3191461T/lt unknown
- 2015-08-31 PT PT212039655T patent/PT3977993T/pt unknown
- 2015-08-31 IL IL251037A patent/IL251037B1/en unknown
- 2015-08-31 SI SI201531753T patent/SI3191461T1/sl unknown
- 2015-08-31 KR KR1020177006011A patent/KR102004059B1/ko active Active
- 2015-08-31 SG SG11201700958YA patent/SG11201700958YA/en unknown
- 2015-08-31 FI FIEP24152053.5T patent/FI4349406T3/fi active
- 2015-08-31 BR BR112017003421-2A patent/BR112017003421B1/pt active IP Right Grant
- 2015-08-31 CN CN201580048168.2A patent/CN106715405A/zh active Pending
- 2015-08-31 SI SI201532001T patent/SI3977993T1/sl unknown
- 2015-08-31 ES ES21203965T patent/ES2975633T3/es active Active
- 2015-08-31 HR HRP20211834TT patent/HRP20211834T1/hr unknown
- 2015-08-31 EP EP24152053.5A patent/EP4349406B1/en active Active
- 2015-08-31 HU HUE15771276A patent/HUE056583T2/hu unknown
- 2015-08-31 SI SI201532089T patent/SI4349406T1/sl unknown
- 2015-08-31 PT PT241520535T patent/PT4349406T/pt unknown
- 2015-08-31 PL PL15771276T patent/PL3191461T3/pl unknown
- 2015-08-31 MX MX2017002954A patent/MX374012B/es active IP Right Grant
- 2015-08-31 DK DK24152053.5T patent/DK4349406T3/da active
- 2015-08-31 RS RS20211481A patent/RS62634B1/sr unknown
- 2015-08-31 DK DK21203965.5T patent/DK3977993T3/da active
- 2015-08-31 EP EP15771276.1A patent/EP3191461B1/en active Active
- 2015-08-31 WO PCT/IB2015/056597 patent/WO2016038500A1/en not_active Ceased
- 2015-08-31 ES ES15771276T patent/ES2901785T3/es active Active
- 2015-08-31 HU HUE21203965A patent/HUE065233T2/hu unknown
- 2015-08-31 EP EP21203965.5A patent/EP3977993B1/en active Active
- 2015-08-31 US US15/509,343 patent/US9770441B1/en active Active
- 2015-09-02 JP JP2015172636A patent/JP2016065042A/ja not_active Withdrawn
- 2015-09-03 CA CA2903194A patent/CA2903194A1/en not_active Abandoned
- 2015-09-07 TW TW104129562A patent/TWI644902B/zh active
-
2019
- 2019-12-02 JP JP2019218244A patent/JP7357525B2/ja active Active
-
2021
- 2021-11-09 JP JP2021182622A patent/JP2022024014A/ja not_active Withdrawn
- 2021-12-16 CY CY20211101109T patent/CY1124843T1/el unknown
-
2023
- 2023-07-13 JP JP2023115087A patent/JP2023134645A/ja active Pending
-
2025
- 2025-04-15 JP JP2025066606A patent/JP2025108584A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016065042A5 (enExample) | ||
| JP2014526498A5 (enExample) | ||
| HRP20211834T1 (hr) | Kristalni čvrsti oblici 6-karboksi-2-(3,5-diklorfenil)benzoksazola | |
| RU2014109676A (ru) | Твердые формы ингибитора диссоциации транстиретина | |
| HRP20210748T1 (hr) | Postupak priprave spojeva s aktivnošću inhibitora hiv integraze | |
| JP2015010091A5 (enExample) | ||
| HRP20161742T1 (hr) | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona | |
| JP2018024682A5 (enExample) | ||
| HRP20210507T1 (hr) | Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku | |
| RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
| JP2011168587A5 (enExample) | ||
| EA200802119A1 (ru) | Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат | |
| JP2018035160A5 (enExample) | ||
| MX373612B (es) | Cristal del compuesto alquinil benceno 3,5-disustituido. | |
| JP2016041701A5 (enExample) | ||
| EA201000384A1 (ru) | Новая полиморфная форма ротиготина и способ её получения | |
| WO2016164763A8 (en) | Compositions and methods for treating cns disorders | |
| ME02655B (me) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| JP2019510768A5 (enExample) | ||
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| JP2014530818A5 (enExample) | ||
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
| WO2011133441A3 (en) | Novel synthesis for thiazolidinedione compounds | |
| JP2013503134A5 (enExample) |